Explore the vast range of titles available.

Prior skin image datasets have not addressed patient-level information obtained from multiple skin lesions from the same patient. Though artificial intelligence classification algorithms have achieved expert-level performance in controlled studies examining single images, in practice dermatologists base their judgment holistically from multiple lesions on the same patient. The 2020 SIIM-ISIC Melanoma Classification challenge dataset described herein was constructed to address this discrepancy between prior challenges and clinical practice, providing for each image in the dataset an identifier allowing lesions from the same patient to be mapped to one another. This patient-level contextual information is frequently used by clinicians to diagnose melanoma and is especially useful in ruling out false positives in patients with many atypical nevi. The dataset represents 2,056 patients (20.8% with at least one melanoma, 79.2% with zero melanomas) from three continents with an average of 16 lesions per patient, consisting of 33,126 dermoscopic images and 584 (1.8%) histopathologically confirmed melanomas compared with benign melanoma mimickers. Measurement(s) melanoma • Skin Lesion Technology Type(s) Dermoscopy • digital curation Factor Type(s) approximate age • sex • anatomic site Sample Characteristic - Organism Homo sapiens Machine-accessible metadata file describing the reported data: https://doi.org/10.6084/m9.figshare.13070345

Advancements in dermatological artificial intelligence research require high-quality and comprehensive datasets that mirror real-world clinical scenarios. We introduce a collection of 18,946 dermoscopic images spanning from 2010 to 2016, collated at the Hospital Clínic in Barcelona, Spain. The BCN20000 dataset aims to address the problem of unconstrained classification of dermoscopic images of skin cancer, including lesions in hard-to-diagnose locations such as those found in nails and mucosa, large lesions which do not fit in the aperture of the dermoscopy device, and hypo-pigmented lesions. Our dataset covers eight key diagnostic categories in dermoscopy, providing a diverse range of lesions for artificial intelligence model training. Furthermore, a ninth out-of-distribution (OOD) class is also present on the test set, comprised of lesions which could not be distinctively classified as any of the others. By providing a comprehensive collection of varied images, BCN20000 helps bridge the gap between the training data for machine learning models and the day-to-day practice of medical practitioners. Additionally, we present a set of baseline classifiers based on state-of-the-art neural networks, which can be extended by other researchers for further experimentation.

Accurate prognostication is essential to guide clinical management in localised cutaneous melanoma (CM), the form of skin cancer with the highest mortality. While the tumour microenvironment (TME) plays a key role in disease progression, current staging systems rely on limited tumour features and exclude key clinicopathological prognostic features. Here we show that MelanoMAP, a multimodal AI model integrating TME-derived digital biomarkers and clinicopathological features from over 3,500 histology slides, improves prognostication of localised CM. MelanoMAP achieved a C-index of 0.82, a 24% improvement over traditional AJCC staging (0.66) and consistently outperformed clinicopathological-only models across six international patient cohorts. SHAP analysis identified TME-derived digital biomarkers, alongside traditional clinicopathological factors including age, mitotic count, and Breslow depth, were critical determinants of metastatic risk. MelanoMAP establishes a potential foundation for precision oncology in CM, demonstrating how AI-driven digital biomarkers can advance personalised prognostication and inform clinical-decision making. Melanoma staging in early stage cutaneous melanoma currently excludes relevant pathology features. Here the authors develop MelanoMAP to integrate pathology images and clinical data to predict melanoma spread.

IntroductionImmunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, have significantly improved the clinical outcomes of various malignancies. However, they also cause immune-related adverse events (irAEs) that can be challenging to predict, prevent and treat. Although they likely interact with health-related quality of life (HRQoL), most existing evidence on this topic has come from clinical trials with eligibility criteria that may not accurately reflect real-world settings. The QUALITOP project will study HRQoL in relation to irAEs and its determinants in a real-world study of patients treated with immunotherapy.Methods and analysisThis international, observational, multicentre study takes place in France, the Netherlands, Portugal and Spain. We aim to include about 1800 adult patients with cancer treated with immunotherapy in a specifically recruited prospective cohort, and to additionally obtain data from historical real-world databases (ie, databiobanks) and medical administrative registries (ie, national cancer registries) in which relevant data regarding other adult patients with cancer treated with immunotherapy has already been stored. In the prospective cohort, clinical health status, HRQoL and psychosocial well-being will be monitored until 18 months after treatment initiation through questionnaires (at baseline and 3, 6, 12 and 18 months thereafter), and by data extraction from electronic patient files. Using advanced statistical methods, including causal inference methods, artificial intelligence algorithms and simulation modelling, we will use data from the QUALITOP cohort to improve the understanding of the complex relationships among treatment regimens, patient characteristics, irAEs and HRQoL.Ethics and disseminationAll aspects of the QUALITOP project will be conducted in accordance with the Declaration of Helsinki and with ethical approval from a suitable local ethics committee, and all patients will provide signed informed consent. In addition to standard dissemination efforts in the scientific literature, the data and outcomes will contribute to a smart digital platform and medical data lake. These will (1) help increase knowledge about the impact of immunotherapy, (2) facilitate improved interactions between patients, clinicians and the general population and (3) contribute to personalised medicine.Trial registration numberNCT05626764.

A Correction to this paper has been published: https://doi.org/10.1038/s41597-021-00879-x.

A Correction to this paper has been published: https://doi.org/10.1038/s41597-021-00865-3.

Background: There have been multiple studies on the use of Doppler ultrasound to define skin inflammation, but the visible vessels of healthy skin have yet to be described. Objective: This study aimed to evaluate the visible vessels of healthy skin using Doppler ultrasound. Methods: Prospective multicenter study using Doppler ultrasound to analyze healthy skin. The color percentage, flow velocity, and maximum vessel diameter were calculated. Results: 943 images from 152 patients were recorded. The most frequently used mode was color Doppler (40.6%), followed by power Doppler (30.4%). Visible vessels were detected in 18.23%; in positive Doppler images, color occupied less than 5%. The malar region exhibited the highest visible vessels. The 22 MHz probe detected smaller vessels with slower flows than the 18 MHz probe. Spectral Doppler showed peak systolic values of less than 10 cm/s and a vessel diameter of less than 1 mm. In most of the participating centers, the operators had less than 10 years of experience in performing skin ultrasound examinations. Sensitivity of the Doppler may vary according to the device. Conclusions: With the used ultrasound equipment, it was uncommon to visualize vessels in healthy skin. When seen, they covered less than 5% of the image with low flow and small size.

We propose a patch sampling strategy based on a sequential Monte-Carlo method for high resolution image classification in the context of Multiple Instance Learning. When compared with grid sampling and uniform sampling techniques, it achieves higher generalization performance. We validate the strategy on two artificial datasets and two histological datasets for breast cancer and sun exposure classification.

In this work we approach the brain tumor segmentation problem with a cascade of two CNNs inspired in the V-Net architecture \\cite{VNet}, reformulating residual connections and making use of ROI masks to constrain the networks to train only on relevant voxels. This architecture allows dense training on problems with highly skewed class distributions, such as brain tumor segmentation, by focusing training only on the vecinity of the tumor area. We report results on BraTS2017 Training and Validation sets.

This article summarizes the BCN20000 dataset, composed of 19424 dermoscopic images of skin lesions captured from 2010 to 2016 in the facilities of the Hospital Clínic in Barcelona. With this dataset, we aim to study the problem of unconstrained classification of dermoscopic images of skin cancer, including lesions found in hard-to-diagnose locations (nails and mucosa), large lesions which do not fit in the aperture of the dermoscopy device, and hypo-pigmented lesions. The BCN20000 will be provided to the participants of the ISIC Challenge 2019, where they will be asked to train algorithms to classify dermoscopic images of skin cancer automatically.